IFRX vs. RLYB, YS, VTVT, SLS, SCYX, LABP, ASMB, LTRN, DERM, and ANEB
Should you be buying InflaRx stock or one of its competitors? The main competitors of InflaRx include Rallybio (RLYB), YS Biopharma (YS), vTv Therapeutics (VTVT), SELLAS Life Sciences Group (SLS), SCYNEXIS (SCYX), Landos Biopharma (LABP), Assembly Biosciences (ASMB), Lantern Pharma (LTRN), Journey Medical (DERM), and Anebulo Pharmaceuticals (ANEB). These companies are all part of the "pharmaceutical preparations" industry.
InflaRx (NASDAQ:IFRX) and Rallybio (NASDAQ:RLYB) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, valuation, earnings, community ranking, profitability, media sentiment, analyst recommendations, risk and institutional ownership.
In the previous week, InflaRx had 3 more articles in the media than Rallybio. MarketBeat recorded 14 mentions for InflaRx and 11 mentions for Rallybio. Rallybio's average media sentiment score of 0.82 beat InflaRx's score of 0.73 indicating that Rallybio is being referred to more favorably in the news media.
42.4% of InflaRx shares are held by institutional investors. Comparatively, 90.3% of Rallybio shares are held by institutional investors. 16.3% of InflaRx shares are held by company insiders. Comparatively, 7.4% of Rallybio shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
InflaRx's return on equity of -37.37% beat Rallybio's return on equity.
InflaRx currently has a consensus price target of $13.50, indicating a potential upside of 980.00%. Rallybio has a consensus price target of $12.20, indicating a potential upside of 585.39%. Given InflaRx's stronger consensus rating and higher probable upside, research analysts clearly believe InflaRx is more favorable than Rallybio.
InflaRx received 200 more outperform votes than Rallybio when rated by MarketBeat users. However, 75.00% of users gave Rallybio an outperform vote while only 64.19% of users gave InflaRx an outperform vote.
InflaRx has a beta of 1.26, meaning that its stock price is 26% more volatile than the S&P 500. Comparatively, Rallybio has a beta of -1.63, meaning that its stock price is 263% less volatile than the S&P 500.
InflaRx has higher revenue and earnings than Rallybio. InflaRx is trading at a lower price-to-earnings ratio than Rallybio, indicating that it is currently the more affordable of the two stocks.
Summary
InflaRx beats Rallybio on 12 of the 17 factors compared between the two stocks.
Get InflaRx News Delivered to You Automatically
Sign up to receive the latest news and ratings for IFRX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding IFRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
